Pharmaceutical meetings and events continue to grow as integral elements in overall promotion of prescription drugs, according to Newtown, PA-based Scott-Levin's "Physician Meeting & Event Audit," a survey of more than 3,400 doctors. The survey found that pharmaceutical companies spent $1.9 billion on events for physicians in 2000, 14% more than in 1999.
Pharmaceutical meetings and events continue to grow as integral elements in overall promotion of prescription drugs, according to Newtown, PA-based Scott-Levin's "Physician Meeting & Event Audit," a survey of more than 3,400 doctors. The survey found that pharmaceutical companies spent $1.9 billion on events for physicians in 2000, 14% more than in 1999.
By comparison, the industry spent the same amount on direct-to-consumer ads for prescription products between January and September 2000.
The survey also found that pharmaceutical companies devoted an average of 17% of their promotional budgets to meetings and events, about the same proportion as in 1999. Total promotional spending for prescription drugs rose from $9 billion to $10.4 billion in 2000.
Scott-Levin projects that 314,022 physician events were held in 2000, an increase of about 11%. Event activity almost doubled between 1996 and 2000. PR
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.